Nuvation Bio, Inc. (NUVB)
NYSEHealth CareBiotechnologySnapshot 2026-09-09
$6.52-1.36%
Close 2026-09-09 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Net income positive at $5.397 million in 2026-Q1: EPS -0.18 vs target 0.0.
Nuvation Bio raised its 2026 revenue guidance to $83 million. It made $5.4 million net income in 2026-Q1. The company has a deal with Eisai to develop a cancer drug. These show improving business and growth potential.
Nuvation Bio still loses money overall. Analysts expect negative earnings in 2026 and 2027. The company took on new debt recently. These risks could hurt the turnaround.
The market has no clear consensus revenue growth or fair value. Our view sees potential in the raised revenue guidance and early profit, but risks remain from losses and debt.
Breaks if: Debt causes cash flow problems or growth stalls
Breaks if: Net income falls below zero in 2026-Q1
Revenue falls below $83 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
NUVB represents a speculative growth investment with a focus on expanding its product offerings. The current thesis state is intact, but the company faces challenges due to its loss-making status and elevated risk factors.
The market currently prices NUVB as justified, reflecting a low fragility tier. There is an expectations gap, indicating that the market may have already accounted for some of the challenges NUVB faces compared to its peers.
Management is focused on expanding adoption of its key product, IBTROZI, which has shown recent revenue growth. However, the overall financial performance remains neutral, and near-term risks are elevated due to a potential for earnings misses in a high-miss-rate industry.
The future performance of NUVB hinges on its ability to maintain revenue growth, particularly from IBTROZI, and the success of its clinical programs. Additionally, broader sector performance, especially among key competitors, will be critical in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Nuvation Bio's earnings missed expectations. This raises concerns about its financial health. However, an analyst expects higher peak sales for its key drugs. Cantor Fitzgerald estimates U.S. peak sales of $965 million for Ibtrozi. They also estimate $1.9 billion for safusidenib. This suggests potential revenue growth for the company.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Partnership with Eisai ends or fails
Over the next 1 to 3 years, NUVB's prospects will depend on its execution of growth strategies and the overall health of the healthcare sector. Not investment advice.